Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02866981 · ClinicalTrials.gov registry record · Phase 2
Observation for Patients With Asymptomatic CNS Metastatic Disease
A Phase 2 study, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02866981 is a Phase 2 study that has completed, run by The Cooper Health System. The registered enrollment target is 33 participants.
The verdict
NCT02866981, a Phase 2 study, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this registry is to determine if select patients with CNS metastatic disease can be safely observed rather than treated. The investigators hypothesize that there is a subset of patients with small asymptomatic CNS mets that do not require treatment, these patients can simply be observed and will not have CNS progression.
Interventions
- OTHER Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02866981
The ClinicalTrials.gov registry entry for NCT02866981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observation is the first listed.
NCT02866981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02866981 about?
NCT02866981 is a clinical study titled "Observation for Patients With Asymptomatic CNS Metastatic Disease". The purpose of this registry is to determine if select patients with CNS metastatic disease can be safely observed rather than treated. The investigators hypothesize that there is a subset of patients with small asymptomatic CNS mets that do not require treatment, these patients can simply be observ...
What is the current status of trial NCT02866981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2014-02. Estimated completion is 2017-12-01.
What interventions are being tested in trial NCT02866981?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT02866981?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.